<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Ultrasound</journal-id><journal-title-group><journal-title>Cardiovascular Ultrasound</journal-title></journal-title-group><issn pub-type="epub">1476-7120</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19891770</article-id><article-id pub-id-type="pmc">2779183</article-id><article-id pub-id-type="publisher-id">1476-7120-7-52</article-id><article-id pub-id-type="doi">10.1186/1476-7120-7-52</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The ischemic preconditioning effect of adenosine in patients with ischemic heart disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sadigh</surname><given-names>Bita</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bita.sadigh@karolinska.se</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Quintana</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>miguel.quintana@ki.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Sylv&#x000e9;n</surname><given-names>Christer</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>christer.sylven@ki.se</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Berglund</surname><given-names>Margareta</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>margareta.berglund@karolinska.se</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Brodin</surname><given-names>Lars &#x000c5;ke</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>lars-ake.brodin@sth.kth.se</email></contrib></contrib-group><aff id="I1"><label>1</label>The Karolinska Institute, at the Department of Cardiology, Karolinska University Hospital, Huddinge, Stockholm, Sweden</aff><aff id="I2"><label>2</label>Institution of Laboratory Medicine, Department of Cardiology, Hospital de Torrevieja, Alicante, Spain</aff><aff id="I3"><label>3</label>Institution of Laboratory Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2009</year></pub-date><volume>7</volume><fpage>52</fpage><lpage>52</lpage><history><date date-type="received"><day>16</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Sadigh et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Sadigh et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.cardiovascularultrasound.com/content/7/1/52"/><abstract><sec><title>Introduction</title><p><italic>In vivo </italic>and <italic>in vitro </italic>evidence suggests that adenosine and its agonists play key roles in the process of ischemic preconditioning. The effects of low-dose adenosine infusion on ischemic preconditioning have not been thoroughly studied in humans.</p></sec><sec><title>Aims</title><p>We hypothesised that a low-dose adenosine infusion could reduce the ischemic burden evoked by physical exercise and improve the regional left ventricular (LV) systolic function.</p></sec><sec><title>Materials and methods</title><p>We studied nine severely symptomatic male patients with severe coronary artery disease. Myocardial ischemia was induced by exercise on two separate occasions and quantified by Tissue Doppler Echocardiography. Prior to the exercise test, intravenous low-dose adenosine or placebo was infused over ten minutes according to a randomized, double blind, cross-over protocol. The LV walls were defined as ischemic if a reduction, no increment, or an increment of &#x0003c; 15% in peak systolic velocity (PSV) was observed during maximal exercise compared to the baseline values observed prior to placebo-infusion. Otherwise, the LV walls were defined as non-ischemic.</p></sec><sec><title>Results</title><p>PSV increased from baseline to maximal exercise in non-ischemic walls both during placebo (<italic>P </italic>= 0.0001) and low-dose adenosine infusion (<italic>P </italic>= 0.0009). However, in the ischemic walls, PSV increased only during low-dose adenosine infusion <italic>(P </italic>= 0.001), while no changes in PSV occurred during placebo infusion (<italic>P </italic>= NS).</p></sec><sec><title>Conclusion</title><p>Low-dose adenosine infusion reduced the ischemic burden and improved LV regional systolic function in the ischemic walls of patients with exercise-induced myocardial ischemia, confirming that adenosine is a potential preconditioning agent in humans.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Ischemic preconditioning protects the heart through brief episodes of ischemia and renders the myocardium resistant to subsequent ischemic insults. The potential beneficial effects of ischemic preconditioning include the preservation of the left ventricular (LV) systolic and diastolic functions[<xref ref-type="bibr" rid="B1">1</xref>], the preservation of adenosine triphosphate levels in myocardial biopsy specimens[<xref ref-type="bibr" rid="B1">1</xref>], and the prevention of arrhythmias by minimizing QT and JT dispersion[<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Ischemic preconditioning is triggered by the binding of several humoral factors such as adenosine, bradykinin, and opioids to their cardiac receptors[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>], thereby initiating a series of complex and divergent signal cascades that eventually converge on protein kinase C. The cardioprotective effect of ischemic preconditioning seems to be biphasic, with an early opioid mediated phase occurring within minutes from the initial ischemic insult and lasting for two to three hours, and a late phase becoming apparent 12 to 24 hours later, lasting three to four days and requiring <italic>de novo </italic>protein synthesis[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. The major cellular mechanism responsible for the beneficial effects of ischemic preconditioning seems to be the opening of K<sub>ATP </sub>channels either on the cardiac sarcolemmal or mitochondrial membrane [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The aim of this study was to explore whether low-dose adenosine infusion exerts an ischemic preconditioning effect in severely symptomatic patients with advanced coronary artery disease.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>We studied nine male patients, mean age 74 years, (range 58-79 years), with severe coronary artery disease (eight with three-vessel and one with two-vessel disease) and severely symptomatic (CCS angina functional class II-III). Except for one patient who had dynpnea, the rest suffered from daily angina. Eight of the patients underwent later coronary bypass grafting (CABG) and one patient with earlier CABG underwent percutanous coronary intervention. All patients had normal global LV systolic function at rest except for one patient who had mildly depressed global LV systolic function (LV ejection fraction &#x02248; 45%). Three patients had a history of myocardial infarction, three had a history of systemic arterial hypertension, three had a history of paroxysmal atrial fibrillation, three had a mild form of chronic renal failure, and none had a history of diabetes mellitus. All patients were treated with aspirin, beta-blockers, long acting nitrates and calcium channel blockers and seven with either angiotensine converting enzyme inhibitors or angiotensine II receptors blockers.</p></sec><sec><title>Standard echocardiography</title><p>We obtained a baseline two-dimensional echocardiography with superimposed Tissue Doppler Echocardiography (TDE) images using a multi-Hertz transducer with commercially available equipment (Vivid 7, GE Vingmed, Horten, Norway) for all patients prior to bicycle exercise stress echocardiography test. Standard parasternal short and long axis views, as well as apical two, three, and four chamber views, were digitized during three consecutive cardiac cycles in cine loop format for off-line analysis.</p></sec><sec><title>Exercise stress echocardiography test protocol</title><p>The patients underwent two separate exercise stress echocardiography test in semi-supine position on a specially designed, table-mounted bicycle ergometer. The initial workload was 25 Watts with increments of 10 Watts added every minute. At each stage, the heart rate, systolic blood pressure, and a 12-lead ECG were recorded. We obtained standard echocardiographic images of five consecutive cardiac cycles containing TDE information at rest, sub-maximal workload (heart rate = 70% of the expected maximal heart rate), maximal workload, and recovery phases (one to two minutes after the exercise); all measurements were digitally recorded and stored. Stopping criteria for exercise test was either severe chest pain or achieved 85% of maximal expected heart rate (220-age).</p></sec><sec><title>Study protocol</title><p>An intravenous infusion of either low-dose adenosine (35 &#x003bc;g/kg/min) or placebo (saline infusion) was given in a double-blind fashion over 10 minutes prior to the start of the exercise test. The order of the drug administration was randomly selected and the sequence of infusions was inverted on the second occasion; the first and second occasions occurred at least one day apart, median 3 days (range 1 to 5 days) (Figure <xref ref-type="fig" rid="F1">1</xref>). The rationale to select this dosage lies on previous studies showing that it had an analgetic effect[<xref ref-type="bibr" rid="B8">8</xref>], doses between 50 and 70 &#x003bc;g/kg/min may have a positive effect while doses higher than 70 &#x003bc;g/kg/min provoked ischemia[<xref ref-type="bibr" rid="B9">9</xref>] in patients with coronary artery disease.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Study protocol</bold>. The dotted lines represent absence of infusion either of placebo or of adenosine. Echocardiographic images were obtained before adenosine/placebo infusions and at each stage of the exercise test.</p></caption><graphic xlink:href="1476-7120-7-52-1"/></fig></sec><sec><title>Tissue Doppler echocardiography off-line analysis</title><p>The analysis of the echocardiographic images was done by one of the investigators (MQ) blinded to the sequence of drug administration. However, the images corresponding to each stage of the protocol were known as the heart rate at rest and at peak exercise were clearly discernible. A sample volume was positioned on the region of interest at the basal segment of the four LV walls (septal, lateral, inferior, and anterior) to obtain a myocardial velocity profile (Figure <xref ref-type="fig" rid="F2">2</xref>). We analyzed both the systolic and diastolic phases of the velocity profile. We defined peak systolic velocity (PSV) as the peak velocity during ejection. We also measured peak velocity at early diastole (E'-wave) and peak velocity at the late diastole (A'-wave). The longitudinal A-V plane displacement was calculated by time integration of the PSV. In addition, the degree of myocardial compression/deformation as strain (S) and strain rate (SR) were also calculated.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Tissue Doppler echocardiography</bold>. To the left, an apical four-chamber view picture with the sample volume placed at the basal portion of the septal wall. On the right, all the variables extracted from on-line recording.</p></caption><graphic xlink:href="1476-7120-7-52-2"/></fig><p>In order to assess the LV regional systolic function and to detect the presence of regional myocardial ischemia, the LV walls were categorized as ischemic or non-ischemic: a LV wall was defined as ischemic if a reduction, no increment, or an increment of &#x0003c;15% in PSV, was observed during maximal work load compared to baseline preceding placebo-infusion; otherwise, the LV walls were defined as non-ischemic.</p></sec><sec><title>Statistical Analysis</title><p>Data are presented as mean &#x000b1; standard deviation (SD). Statistical comparisons were performed by analysis of variance (ANOVA) with repeated measures. Post hoc comparisons between groups were performed using the Tukey test.</p></sec><sec><title>Ethics</title><p>The local Ethics Committee at the Karolinska University Hospital, Huddinge, approved the study. All participants gave written informed consent.</p></sec></sec><sec><title>Results</title><p>There were no significant differences in maximal work capacity, hemodynamic parameters including heart rate and blood pressure or ST-depression (Table <xref ref-type="table" rid="T1">1</xref>). We observed a significant increment in PSV during maximal stress compared to rest during both the adenosine and placebo infusions; however, we observed no significant differences in PSV between low-dose adenosine and placebo infusions (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Hemodynamic parameters (heart rate, blood pressure), work capacity (Watts) and Tissue Doppler echocardiography variables (expressed as the average of the four LV walls) measured at baseline and maximal work loud during adenosine and placebo infusions</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="2">Adenosine</th><th align="center" colspan="2">Placebo</th></tr></thead><tbody><tr><td align="center"><bold>Variables</bold></td><td align="center"><bold>Baseline</bold></td><td align="center"><bold>Peak</bold></td><td align="center"><bold>Baseline</bold></td><td align="center"><bold>Peak</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left"><bold>Heart rate, bpm</bold></td><td align="center">59 &#x000b1; 11</td><td align="center">104 &#x000b1; 13*</td><td align="center">62 &#x000b1; 14</td><td align="center">106 &#x000b1; 13*</td></tr><tr><td align="left"><bold>SBP, mm Hg</bold></td><td align="center">143 &#x000b1; 12</td><td align="center">172 &#x000b1; 18*</td><td align="center">148 &#x000b1; 20</td><td align="center">169 &#x000b1; 28*</td></tr><tr><td align="left"><bold>Watts</bold></td><td align="center">00.0 &#x000b1; 0.0</td><td align="center">83 &#x000b1; 19</td><td align="center">00.0 &#x000b1; 0.0</td><td align="center">83 &#x000b1; 28</td></tr><tr><td align="left"><bold>ST depression</bold></td><td/><td align="center">1.8 &#x000b1; 1.4</td><td/><td align="center">1.4 &#x000b1; 1.0</td></tr><tr><td align="left"><bold>PSV, cm/s</bold></td><td align="center">5.5 &#x000b1; 1.6</td><td align="center">6.4 &#x000b1; 3.2*</td><td align="center">5.5 &#x000b1; 1.6</td><td align="center">7.6 &#x000b1; 2.6*</td></tr><tr><td align="left"><bold>A-V plane, mm</bold></td><td align="center">9.6 &#x000b1; 2.7</td><td align="center">10.9 &#x000b1; 4.4*</td><td align="center">9.0 &#x000b1; 2.6</td><td align="center">11.7 &#x000b1; 4.3*</td></tr><tr><td align="left"><bold>S%</bold></td><td align="center">17.4 &#x000b1; 5.1</td><td align="center">23.4 &#x000b1; 7.4*</td><td align="center">16.5 &#x000b1; 3.8</td><td align="center">22.1 &#x000b1; 7.2*</td></tr><tr><td align="left"><bold>SR</bold><sup>-1</sup></td><td align="center">-0.9 &#x000b1; 0.3</td><td align="center">-1.9 &#x000b1; 0.5*</td><td align="center">-1.0 &#x000b1; 0.2</td><td align="center">-1.9 &#x000b1; 1.5*</td></tr><tr><td align="left"><bold>E'-wave, cm/s</bold></td><td align="center">6.5 &#x000b1; 1.9</td><td align="center">8.8 &#x000b1; 4.0*</td><td align="center">5.5 &#x000b1; 2.3</td><td align="center">8.5 &#x000b1; 4.2*</td></tr><tr><td align="left"><bold>A'-wave, cm/s</bold></td><td align="center">4.9 &#x000b1; 2.4</td><td align="center">5.1 &#x000b1; 3.6</td><td align="center">4.9 &#x000b1; 2.5</td><td align="center">4.1 &#x000b1; 2.9</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as means &#x000b1; SD.</p><p>Abbreviations: A' = late diastolic A-wave; A-V = atrio-ventricular plane displacement; bpm = beats per minute; E' = early diastolic E-wave; PSV = peak systolic velocity; SBP = systolic blood pressure, S% = strain; SR = strain rate.</p><p>* <italic>P </italic>&#x0003c; 0.01 Peak versus baseline</p></table-wrap-foot></table-wrap><p>According to the pre-defined criteria, 12 of the 36 LV walls in the nine patients were found to be ischemic during the placebo infusion. When milder criteria were used to define LV wall ischemia, i.e. a reduction, no increment, or an increment of &#x0003c;25% in peak systolic velocity, 15 of the 36 LV walls were found to be ischemic.</p><p>In the ischemic walls, the increment in PSV was higher during adenosine infusion as compared to placebo (<italic>P </italic>&#x0003c; 0.001; Figure <xref ref-type="fig" rid="F3">3</xref>). The same pattern was seen in AV-plane displacement during systole, and E'-wave (Table <xref ref-type="table" rid="T2">2</xref>). There were no significant differences in A'-wave and strain rate according to the ischemic response during low-dose adenosine infusion or placebo (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Tissue Doppler echocardiography of ischemic and non ischemic LV walls during baseline and maximal work loud during low dose adenosine and placebo infusions</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="4">Adenosine</th><th align="center" colspan="4">Pacebo</th></tr></thead><tbody><tr><td align="center"><bold>Variables</bold></td><td align="center" colspan="2"><bold>Ischemic walls</bold></td><td align="center" colspan="2"><bold>Non ischemic walls</bold></td><td align="center" colspan="2"><bold>Ischemic walls</bold></td><td align="center" colspan="2"><bold>Non ischemic walls</bold></td></tr><tr><td colspan="9"><hr/></td></tr><tr><td/><td align="center"><bold><italic>Rest</italic></bold></td><td align="center"><bold><italic>Peak</italic></bold></td><td align="center"><bold><italic>Rest</italic></bold></td><td align="center"><bold><italic>Peak</italic></bold></td><td align="center"><bold><italic>Rest</italic></bold></td><td align="center"><bold><italic>Peak</italic></bold></td><td align="center"><bold><italic>Rest</italic></bold></td><td align="center"><bold><italic>Peak</italic></bold></td></tr><tr><td colspan="9"><hr/></td></tr><tr><td align="left"><bold>PSV, cm/s</bold></td><td align="center">5.1 &#x000b1; 1.4</td><td align="center">6.9 &#x000b1; 2.1*&#x000a5;</td><td align="center">5.6 &#x000b1; 1.9</td><td align="center">7.3 &#x000b1; 2.7*</td><td align="center">6.0 &#x000b1; 2.0</td><td align="center">5.6 &#x000b1; 1.6</td><td align="center">5.4 &#x000b1; 1.5</td><td align="center">9.1 &#x000b1; 2.7*</td></tr><tr><td align="left"><bold>A-V plane, mm</bold></td><td align="center">9.4 &#x000b1; 2.6</td><td align="center">10.3 &#x000b1; 3.2*&#x000a5;</td><td align="center">10.3 &#x000b1; 3.7</td><td align="center">11.6 &#x000b1; 5.8*</td><td align="center">10.7 &#x000b1; 2.2</td><td align="center">9.7 &#x000b1; 2.7</td><td align="center">8.4 &#x000b1; 3.2</td><td align="center">13.0 &#x000b1; 5.4*</td></tr><tr><td align="left"><bold>S%</bold></td><td align="center">16 &#x000b1; 3</td><td align="center">24 &#x000b1; 4</td><td align="center">16 &#x000b1; 6</td><td align="center">23 &#x000b1; 12*</td><td align="center">17 &#x000b1; 4</td><td align="center">13 &#x000b1; 5</td><td align="center">16 &#x000b1; 6</td><td align="center">27 &#x000b1; 5*</td></tr><tr><td align="left"><bold>SR</bold><sup>-1</sup></td><td align="center">-1.0 &#x000b1; 0.9</td><td align="center">-1.7 &#x000b1; 1.3*</td><td align="center">-1.4 &#x000b1; 0.5</td><td align="center">-2.0 &#x000b1; 1.0*</td><td align="center">-1.6 &#x000b1; 0.5</td><td align="center">-0.9 &#x000b1; 1.6</td><td align="center">-1.2 &#x000b1; 0.5</td><td align="center">-2.6 &#x000b1; 1.8*</td></tr><tr><td align="left"><bold>E'-wave, cm/s</bold></td><td align="center">7.4 &#x000b1; 3.7</td><td align="center">11.9 &#x000b1; 5.4*&#x000a5;</td><td align="center">6.4 &#x000b1; 2.7</td><td align="center">10.1 &#x000b1; 2.4*</td><td align="center">7.8 &#x000b1; 2.3</td><td align="center">9.7 &#x000b1; 5.9*</td><td align="center">5.2 &#x000b1; 2.6</td><td align="center">10.4 &#x000b1; 3.7*</td></tr><tr><td align="left"><bold>A'-wave, cm/s</bold></td><td align="center">6.7 &#x000b1; 1.6</td><td align="center">7.3 &#x000b1; 2.9</td><td align="center">4.3 &#x000b1; 2.6</td><td align="center">6.7 &#x000b1; 1.9*</td><td align="center">6.6 &#x000b1; 1.5</td><td align="center">6.1 &#x000b1; 1.7*</td><td align="center">4.0 &#x000b1; 2.0</td><td align="center">7.1 &#x000b1; 1.5*</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as means &#x000b1; SD.</p><p>As in table 1</p><p>* <italic>P </italic>&#x0003c; 0.01 Peak versus baseline</p><p>&#x000a5; <italic>P </italic>&#x0003c; 0.01 Peak - ischemic walls - adenosine, versus peak - ischemic walls - placebo</p></table-wrap-foot></table-wrap><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Peak systolic velocity at rest and peak exercise on ischemic and non-ischemic walls during adenosine and placebo infusions</bold>.</p></caption><graphic xlink:href="1476-7120-7-52-3"/></fig></sec><sec><title>Discussion</title><p>In this study, a low-dose infusion of adenosine preserved the regional systolic function of LV walls subjected to an exercise-induced ischemic burden. We observed a higher PSV at peak exercise in LV walls rendered ischemic during adenosine infusion than during placebo infusion, suggesting a preconditioning effect of adenosine. The main idea of the study was to investigate the possible preconditioning effect of adenosine infusion in a quantitative manner and thus avoiding any possible bias induced by subjective analysis of wall motion analysis. Therefore, we did not use wall motion score in the diagnosis of myocardial ischemia. The concordance between wall motion core and tissue Doppler imaging in this respect has been reported elsewhere [<xref ref-type="bibr" rid="B10">10</xref>]. Having said this, we do not mean that quantitative stress echocardiography is the gold standard for the detection of myocardial ischemia.</p><p>Alternative mechanisms for preserving the regional systolic function may have been achieved by adenosine-mediated vasodilatation or by the possible unloading effects of adenosine; however, these are unlikely mechanisms because myocardial ischemia would already have caused maximal vasodilatation and the low-dose adenosine infusion was stopped before the exercise stress test, by which time any previously infused adenosine would have been metabolised and could not have had a vasodilatory effect. In addition, heart rate and blood pressure responses did not differ between the two treatments, excluding the possible unloading effect of adenosine.</p><p>Adenosine has been suggested to induce preconditioning[<xref ref-type="bibr" rid="B11">11</xref>] by agonizing its A<sub>1 </sub>and A<sub>3 </sub>receptors; however, some of the protective effects of adenosine might occur via an antiplatelet effect or an anti-inflammatory effect that is totally independent of preconditioning. Clinical trials suggest that some preconditioning mimetics reduce myocardial infarct size when given in conjunction with reperfusion [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>], and may improve survival, especially in selected patients with acute anterior myocardial infarction[<xref ref-type="bibr" rid="B14">14</xref>]. It should be noted that the largely neutral effects observed in the AMISTAD study refers to the possible preconditioning effect of adenosine in a different clinical setting, namely the "reperfusion-injury" provoked by opening the infarct related artery in the context of an ST-elevation acute myocardial infarction.</p><p>In the present experimental model of exercise induced myocardial ischemia detected by TDE technique in humans, it is impossible to be sure that the reported findings were caused by ischemic preconditioning mediated by the activation of adenosine receptors; however excluding the vascular and unloading effects and considering that infusion of 35 &#x003bc;g/kg/min of adenosine give rise to activation of adenosine receptors[<xref ref-type="bibr" rid="B15">15</xref>], the hypothesis of ischemic preconditioning induced by adenosine is highly plausible. Our results are in keeping with Picano et al who by using dipyridamole, which is an adenosine uptake inhibitor reported increased ischemic threshold [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Numerous studies have shown that pre-infarction angina pectoris protects patients who develop acute myocardial infarction [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>], and at least part of this benefit may be due to a preconditioning phenomenon rather than simply recruiting collateral blood flow. Pre-infarction angina pectoris has been associated with smaller myocardial infarct size, decreased prevalence of congestive heart failure, less cardiac death, fewer arrhythmias, and improved cardiac function[<xref ref-type="bibr" rid="B18">18</xref>]. Therefore, it might be possible to treat high risk patients or patients with unstable angina pectoris with preconditioning mimetic agents that stimulate the biochemistry of preconditioning without actually causing ischemia.</p><sec><title>Study limitations</title><p>The small size of this study precludes the extrapolation of our results to all patients with ischemic heart disease, especially to those with mild forms of exercise-induced ischemia. The positive pre-conditioning effects of adenosine were not observed for all parameters reflecting the regional LV systolic function. In fact, strain rate, a measure of "pure" myocardial contractility, was not affected by adenosine. This result could be explained by the low reproducibility of this measure when assessed during exercise[<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Certainly, some degree of ischemic preconditioning induced by angina pectoris did exist among all the patients. However, we do not believe that this fact compromised the results of the study, considering the placebo/controlled and the cross-over character of the study. We used high ischemic limit criteria to define myocardial ischemia by tissue Doppler echocardiography, and when milder criteria that allow for the detection of less severe forms of ischemia were applied, the results were the same. However, if we applied the same ischemic criteria as are used in clinical practice[<xref ref-type="bibr" rid="B21">21</xref>], almost all LV walls were categorized as ischemic, making it impossible to perform adequate statistical analysis. This fact emphasizes that we were studying patients with severe coronary artery disease: severely symptomatic and with severe exercise induced myocardial ischemia.</p></sec><sec><title>Possible clinical implications</title><p>The present results may open the possibilities of testing new therapeutic agents for the treatment of not only high risk patients with preconditioning mimetics that stimulate the biochemistry of preconditioning without actually causing ischemia but also of a vast number of patients with stable angina pectoris with mild to severe symptom in whom coronary revascularisation is impossible or not achievable.</p></sec></sec><sec><title>Conclusion</title><p>Low-dose adenosine infusion reduced the ischemic burden and improved the left ventricular regional systolic function in the ischemic walls of patients with exercise-induced myocardial ischemia, confirming the possible preconditioning effect of adenosine in humans.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BS selected the patients. MQ carried out the stress tests and MQ and BS analysed the data and statistical measurements. MB participated in the stress tests. CS participated in the design of the study and contributed to the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Alkhulaifi</surname><given-names>AM</given-names></name><name><surname>Pugsley</surname><given-names>WB</given-names></name><article-title>Preconditioning the human myocardium</article-title><source>Lancet</source><year>1993</year><volume>342</volume><issue>8866</issue><fpage>276</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)91819-8</pub-id><pub-id pub-id-type="pmid">8101304</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Kotoh</surname><given-names>K</given-names></name><name><surname>Ueyama</surname><given-names>K</given-names></name><name><surname>Misaki</surname><given-names>T</given-names></name><article-title>Myocardial ischemic preconditioning during minimally invasive direct coronary artery bypass grafting attenuates ischemia-induced electrophysiological changes in human ventricle</article-title><source>Jpn J Thorac Cardiovasc Surg</source><year>2003</year><volume>51</volume><issue>4</issue><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1007/s11748-003-0050-3</pub-id><pub-id pub-id-type="pmid">12723584</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Marber</surname><given-names>MS</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><article-title>Myocardial adaptation, stress proteins, and the second window of protection</article-title><source>Ann N Y Acad Sci</source><year>1996</year><volume>793</volume><fpage>123</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1996.tb33510.x</pub-id><pub-id pub-id-type="pmid">8906161</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Post</surname><given-names>H</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><article-title>Ischemic preconditioning. Experimental facts and clinical perspective</article-title><source>Minerva Cardioangiol</source><year>2002</year><volume>50</volume><issue>6</issue><fpage>569</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">12473980</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Gross</surname><given-names>GJ</given-names></name><article-title>Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs</article-title><source>Circulation</source><year>1994</year><volume>89</volume><issue>4</issue><fpage>1769</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">8149542</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Gross</surname><given-names>GJ</given-names></name><name><surname>Auchampach</surname><given-names>JA</given-names></name><article-title>Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs</article-title><source>Circ Res</source><year>1992</year><volume>70</volume><issue>2</issue><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">1310443</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Raphael</surname><given-names>J</given-names></name><name><surname>Drenger</surname><given-names>B</given-names></name><name><surname>Rivo</surname><given-names>J</given-names></name><name><surname>Berenshtein</surname><given-names>E</given-names></name><name><surname>Chevion</surname><given-names>M</given-names></name><name><surname>Gozal</surname><given-names>Y</given-names></name><article-title>Ischemic preconditioning decreases the reperfusion-related formation of hydroxyl radicals in a rabbit model of regional myocardial ischemia and reperfusion: the role of K(ATP) channels</article-title><source>Free Radic Res</source><year>2005</year><volume>39</volume><issue>7</issue><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1080/10715760500148543</pub-id><pub-id pub-id-type="pmid">16036354</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Sylven</surname><given-names>C</given-names></name><name><surname>Eriksson</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Geigant</surname><given-names>E</given-names></name><name><surname>Hallin</surname><given-names>RG</given-names></name><article-title>Analgesic effects of adenosine during exercise-provoked myocardial ischaemia</article-title><source>Neuroreport</source><year>1996</year><volume>7</volume><issue>9</issue><fpage>1521</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">8856712</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Straat</surname><given-names>E</given-names></name><name><surname>Henriksson</surname><given-names>P</given-names></name><name><surname>Edlund</surname><given-names>A</given-names></name><article-title>Adenosine provokes myocardial ischaemia in patients with ischaemic heart disease without increasing cardiac work</article-title><source>J Intern Med</source><year>1991</year><volume>230</volume><issue>4</issue><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.1991.tb00451.x</pub-id><pub-id pub-id-type="pmid">1919425</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Cain</surname><given-names>P</given-names></name><name><surname>Baglin</surname><given-names>T</given-names></name><name><surname>Case</surname><given-names>C</given-names></name><name><surname>Spicer</surname><given-names>D</given-names></name><name><surname>Short</surname><given-names>L</given-names></name><name><surname>Marwick</surname><given-names>TH</given-names></name><article-title>Application of tissue Doppler to interpretation of dobutamine echocardiography and comparison with quantitative coronary angiography</article-title><source>Am J Cardiol</source><year>2001</year><volume>87</volume><issue>5</issue><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(00)01425-9</pub-id><pub-id pub-id-type="pmid">11230833</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Mentzer</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Birjiniuk</surname><given-names>V</given-names></name><name><surname>Khuri</surname><given-names>S</given-names></name><name><surname>Lowe</surname><given-names>JE</given-names></name><name><surname>Rahko</surname><given-names>PS</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Wellons</surname><given-names>HA</given-names></name><name><surname>Barker</surname><given-names>ML</given-names></name><name><surname>Lasley</surname><given-names>RD</given-names></name><article-title>Adenosine myocardial protection: preliminary results of a phase II clinical trial</article-title><source>Ann Surg</source><year>1999</year><volume>229</volume><issue>5</issue><fpage>643</fpage><lpage>649</lpage><comment>discussion 649-650</comment><pub-id pub-id-type="pmid">10235522</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199905000-00006</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Barbagelata</surname><given-names>A</given-names></name><name><surname>Di Carli</surname><given-names>MF</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Garg</surname><given-names>J</given-names></name><name><surname>Birnbaum</surname><given-names>Y</given-names></name><name><surname>Grinfeld</surname><given-names>L</given-names></name><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Goodman</surname><given-names>SG</given-names></name><name><surname>Wagner</surname><given-names>GS</given-names></name><article-title>Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><issue>4</issue><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2004.10.014</pub-id><pub-id pub-id-type="pmid">16209961</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Forman</surname><given-names>MB</given-names></name><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Ross</surname><given-names>AM</given-names></name><name><surname>Alexander</surname><given-names>RW</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><article-title>Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>20</issue><fpage>2400</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehl094</pub-id><pub-id pub-id-type="pmid">16782719</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Quintana</surname><given-names>M</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name><name><surname>Sollevi</surname><given-names>A</given-names></name><name><surname>Kahan</surname><given-names>T</given-names></name><name><surname>Edner</surname><given-names>M</given-names></name><name><surname>Rehnqvist</surname><given-names>N</given-names></name><name><surname>Swahn</surname><given-names>E</given-names></name><name><surname>Kjerr</surname><given-names>AC</given-names></name><name><surname>Nasman</surname><given-names>P</given-names></name><article-title>Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study</article-title><source>Eur J Clin Pharmacol</source><year>2003</year><volume>59</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12743668</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Blardi</surname><given-names>P</given-names></name><name><surname>Laghi Pasini</surname><given-names>F</given-names></name><name><surname>Urso</surname><given-names>R</given-names></name><name><surname>Frigerio</surname><given-names>C</given-names></name><name><surname>Volpi</surname><given-names>L</given-names></name><name><surname>De Giorgi</surname><given-names>L</given-names></name><name><surname>Di Perri</surname><given-names>T</given-names></name><article-title>Pharmacokinetics of exogenous adenosine in man after infusion</article-title><source>Eur J Clin Pharmacol</source><year>1993</year><volume>44</volume><issue>5</issue><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1007/BF00315554</pub-id><pub-id pub-id-type="pmid">8359193</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Picano</surname><given-names>E</given-names></name><name><surname>Lattanzi</surname><given-names>F</given-names></name><name><surname>Masini</surname><given-names>M</given-names></name><name><surname>Distante</surname><given-names>A</given-names></name><name><surname>L'Abbate</surname><given-names>A</given-names></name><article-title>Different degrees of ischemic threshold stratified by the dipyridamole-echocardiography test</article-title><source>Am J Cardiol</source><year>1987</year><volume>59</volume><issue>1</issue><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(87)80072-3</pub-id><pub-id pub-id-type="pmid">3812255</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Rezkalla</surname><given-names>SH</given-names></name><article-title>Cardiac protection during acute myocardial infarction: where do we stand in 2004?</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><issue>2</issue><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.03.068</pub-id><pub-id pub-id-type="pmid">15261919</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Rezkalla</surname><given-names>SH</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name><article-title>Ischemic preconditioning and preinfarction angina in the clinical arena</article-title><source>Nat Clin Pract Cardiovasc Med</source><year>2004</year><volume>1</volume><issue>2</issue><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/ncpcardio0047</pub-id><pub-id pub-id-type="pmid">16265313</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>ZK</given-names></name><name><surname>Tarkka</surname><given-names>MR</given-names></name><name><surname>Eloranta</surname><given-names>J</given-names></name><name><surname>Pehkonen</surname><given-names>E</given-names></name><name><surname>Kaukinen</surname><given-names>L</given-names></name><name><surname>Honkonen</surname><given-names>EL</given-names></name><name><surname>Kaukinen</surname><given-names>S</given-names></name><article-title>Effect of ischemic preconditioning on myocardial protection in coronary artery bypass graft patients: can the free radicals act as a trigger for ischemic preconditioning?</article-title><source>Chest</source><year>2001</year><volume>119</volume><issue>4</issue><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1378/chest.119.4.1061</pub-id><pub-id pub-id-type="pmid">11296170</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>AG</given-names></name><name><surname>Payne</surname><given-names>N</given-names></name><name><surname>Madler</surname><given-names>CF</given-names></name><name><surname>Janerot-Sjoberg</surname><given-names>B</given-names></name><name><surname>Lind</surname><given-names>B</given-names></name><name><surname>Grocott-Mason</surname><given-names>RM</given-names></name><name><surname>Ionescu</surname><given-names>AA</given-names></name><name><surname>Florescu</surname><given-names>N</given-names></name><name><surname>Wilkenshoff</surname><given-names>U</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><article-title>Feasibility and reproducibility of off-line tissue Doppler measurement of regional myocardial function during dobutamine stress echocardiography</article-title><source>Eur J Echocardiogr</source><year>2003</year><volume>4</volume><issue>1</issue><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1053/euje.2002.0610</pub-id><pub-id pub-id-type="pmid">12565062</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Madler</surname><given-names>CF</given-names></name><name><surname>Payne</surname><given-names>N</given-names></name><name><surname>Wilkenshoff</surname><given-names>U</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Derumeaux</surname><given-names>GA</given-names></name><name><surname>Pierard</surname><given-names>LA</given-names></name><name><surname>Engvall</surname><given-names>J</given-names></name><name><surname>Brodin</surname><given-names>LA</given-names></name><name><surname>Sutherland</surname><given-names>GR</given-names></name><name><surname>Fraser</surname><given-names>AG</given-names></name><article-title>Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: optimal diagnostic models using off-line tissue Doppler in the MYDISE study</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>17</issue><fpage>1584</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1016/S0195-668X(03)00099-X</pub-id><pub-id pub-id-type="pmid">12927194</pub-id></mixed-citation></ref></ref-list></back></article>